Aminacrine Hcl
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
AMINACRINE HCL: Evaluation Pending — No Repurposing Prediction Available
One-Sentence Summary
AMINACRINE HCL (9-aminoacridine, an acridine-class compound) has no registered indications in the Singapore market and no mechanism of action data on record. The TxGNN pipeline returned no predicted new indications for this compound in the current run. Without prediction output, clinical trial evidence, or regulatory history, a full repurposing evaluation cannot be completed at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No registered indication on file |
| Predicted New Indication | None generated by TxGNN |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction absent; no supporting studies identified |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN prediction was returned for AMINACRINE HCL in this run, so a mechanism-to-indication bridge cannot be constructed from the current evidence pack.
Mechanism of action data is also unavailable. AMINACRINE HCL is structurally an acridine derivative historically associated with topical antiseptic and DNA-intercalating properties, but this background knowledge is not confirmed by the current data inputs and should not be treated as a validated MOA for repurposing analysis.
Until a DrugBank entry is confirmed, an INN-level MOA is retrieved, and TxGNN prediction scores are generated, the rationale for any new indication remains speculative and cannot be reported here.
Singapore Market Information
AMINACRINE HCL holds no current Health Sciences Authority (HSA) product registrations. There are no active or historical authorisation records to display.
Safety Considerations
Please refer to the package insert and relevant regulatory authority resources for safety information. No warnings, contraindications, or drug interaction data were retrieved for this compound in the current evidence pack.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence pack is missing all three minimum requirements for a repurposing evaluation — a validated DrugBank entry, a TxGNN prediction score, and at least one piece of clinical or preclinical evidence. Proceeding without these data points carries a high risk of generating an unreliable recommendation.
To proceed, the following is needed:
- Confirm drug identity — Verify whether "AMINACRINE HCL" maps to DrugBank entry DB04524 (9-aminoacridine) or another entity; retrieve the confirmed DrugBank ID.
- Retrieve MOA — Query DrugBank API for mechanism of action, pharmacodynamics, and drug category (to determine whether cytotoxicity section applies).
- Re-run TxGNN pipeline — With a confirmed DrugBank ID, re-execute the KG + DL prediction pipeline to generate repurposing candidates.
- Retrieve safety data — Download the product monograph or equivalent reference document to populate warnings and contraindications.
- Reassess market status — Confirm whether any compassionate use, investigational, or historical registrations exist for this compound in Singapore or neighbouring jurisdictions.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.